Comparing safety and efficacy of melatonin, trazodone, and clonazepam on the sleep quality of patients with Parkinson's disease

Comparing safety and efficacy of melatonin, trazodone, and clonazepam on the sleep quality of patients with Parkinson's disease in patients referring to the Neurology Clinic of Roozbeh Hospital

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170821035819N2

Enrollment

Registered

2020-01-29

Start date

2019-06-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep disorder of patients with Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Patients with Parkinson's disease who have sleep disorder, Take 3 mg Melatonin, once a night before bedtime, for one month (This drug is manufactured by Tehran Chem

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with Parkinson's disease who have sleep disorder based on history.

Exclusion criteria

Exclusion criteria: Dementia A history of drug sensitivity

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: First time and After 1 month. Method of measurement: Pittsburgh sleep quality questionnaire.;Daytime sleepiness. Timepoint: First time and After 1 month. Method of measurement: Epworth sleepiness score questionnaire.;Sleep Disorder. Timepoint: First time and After 1 month. Method of measurement: REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVajiheh Aghamollaiy

Tehran University of Medical Sciences

v-aghamollaii@sina.tums.ac.ir+98 21554191515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026